1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Understanding age-specific brain responses to GLP-1RAs is critically important for optimizing obesity treatment strategies across the lifespan. This research could reveal fundamental differences in how the developing …
This research is important because it provides real-world evidence for oral semaglutide's effectiveness outside of highly controlled clinical trial settings. Understanding its performance in routine clinical practice,…
This study is significant because it specifically investigates Semaglutide's efficacy and safety in East Asian subjects, addressing a critical gap in demographic representation within clinical trials for overweight an…
The potential findings from this study could be transformative for obesity management, offering a strategy to mitigate the undesirable muscle loss often associated with significant weight reduction. If successful, thi…
This planned study holds significant promise, as it could establish a novel pharmacological strategy to improve outcomes for atrial fibrillation patients with obesity undergoing ablation. If successful, the findings w…
This research is significant because it explores a novel therapeutic approach for acute pulmonary embolism, a condition with limited long-term treatment options beyond anticoagulation. If Semaglutide demonstrates a po…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment landscape for obesity, potentially offering a more effective therapeutic option than current monotherapies. Cag…
Understanding the long-term impact of semaglutide on appetite and eating behavior is crucial for optimizing obesity treatment strategies. If the study demonstrates sustained improvements in these areas, it could provi…
This foundational Phase 1 study is a critical early step in the development of NN9535 (semaglutide), a compound now widely known for its efficacy in type 2 diabetes and obesity. The successful completion of this trial…
This study is significant because it evaluates a novel approach to personalizing semaglutide treatment, which could revolutionize how obesity and excess weight are managed. By providing healthcare professionals with a…
The successful completion of this trial could have significant implications for the treatment landscape of Type 2 Diabetes. If QLG2065 demonstrates comparable efficacy and safety to Ozempic®, it would introduce a new,…
This study is significant because Semaglutide, a GLP-1 receptor agonist, is already approved for obesity and type 2 diabetes, conditions strongly linked to NAFLD. If the results demonstrate efficacy, it could provide …
The resurgence of cocaine use and related mortality underscores an urgent, unmet need for effective treatments. If Semaglutide proves effective in this pilot study, it could offer a novel pharmacological approach to C…
This study holds significant promise for identifying a novel therapeutic approach for alcohol use disorder (AUD), especially in the context of obesity and fatty liver disease, which are highly prevalent comorbidities.…
This research could fundamentally change our understanding of how GLP-1 RAs exert their metabolic benefits, extending beyond peripheral tissues to direct brain mechanisms. By clarifying the role of semaglutide in enha…
If the anticipated findings are confirmed, this study could provide crucial evidence for the broad metabolic benefits of GLP-1RAs beyond just glycemic control and weight loss. A detailed understanding of how these dru…
As this is a planned study, no results are available yet. However, the researchers anticipate that CagriSema will demonstrate significant improvements in key metabolic markers compared to placebo.
These findings provide compelling real-world evidence supporting tirzepatide's superior efficacy over sitagliptin not only in glycemic control and weight management but critically, in reducing cardiovascular events in…
The potential success of this combination therapy could represent a significant advancement in the treatment landscape for obesity and overweight. By potentially enhancing the already impressive effects of tirzepatide…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
This Phase II IMPACT-ADT trial is profoundly important as it directly addresses a major unmet need in prostate cancer survivorship, aiming to mitigate the severe cardiometabolic side effects of Androgen Deprivation Th…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to effectively treat Binge-Eating Disorder alongside its established benefits for obesity represents a significant advancement in metabolic and psy…
These findings are highly significant, establishing Tirzepatide as a potentially superior treatment option for individuals with Type 2 Diabetes who are at high risk for cardiovascular events. The dual benefits of subs…
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
Persistent obesity after bariatric surgery represents a significant clinical challenge, often leading to comorbidities and reduced quality of life. If Tirzepatide proves effective and safe in this specific patient pop…
This foundational Phase 1 study is crucial for the development of tirzepatide, providing essential data on its pharmacokinetics and safety in humans. Understanding how the drug is absorbed, distributed, metabolized, a…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
This study is incredibly significant because it seeks to confirm if tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for weight management, can directly improve long-term health outcomes beyond just…
This research is crucial because it addresses a significant unmet need for effective treatments targeting adiposopathy in a vulnerable population with CKD and Type 2 Diabetes. Understanding how GLP-1RAs impact fat dis…
This research is critical for advancing the use of real-world evidence (RWE) in medical decision-making and drug development. If the emulation successfully replicates the SUMMIT trial's findings, it would validate the…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to address both obesity and methamphetamine use disorder simultaneously represents a significant advancement in addiction medicine and metabolic he…
If these anticipated findings are confirmed, this study could redefine the therapeutic approach to obesity and its metabolic complications, moving beyond mere weight loss to direct reversal of underlying metabolic dys…
Obtaining real-world data on Tirzepatide is paramount for understanding its performance and tolerability outside the highly controlled environment of earlier clinical trials. This study will provide invaluable insight…